AR043547A1 - Formas polimorficas de rifaximina, procesos para su produccion y uso de las mismas en preparaciones medicinales - Google Patents

Formas polimorficas de rifaximina, procesos para su produccion y uso de las mismas en preparaciones medicinales

Info

Publication number
AR043547A1
AR043547A1 ARP040100781A ARP040100781A AR043547A1 AR 043547 A1 AR043547 A1 AR 043547A1 AR P040100781 A ARP040100781 A AR P040100781A AR P040100781 A ARP040100781 A AR P040100781A AR 043547 A1 AR043547 A1 AR 043547A1
Authority
AR
Argentina
Prior art keywords
rifaximin
water
temperature
crude
ethyl alcohol
Prior art date
Application number
ARP040100781A
Other languages
English (en)
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33187382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR043547(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Publication of AR043547A1 publication Critical patent/AR043547A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • HELECTRICITY
    • H05ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05BELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00Heating by electric, magnetic or electromagnetic fields
    • H05B6/02Induction heating
    • H05B6/10Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12Cooking devices
    • H05B6/1209Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1236Cooking devices induction cooking plates or the like and devices to be used in combination with them adapted to induce current in a coil to supply power to a device and electrical heating devices powered in this way
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • HELECTRICITY
    • H05ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05BELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00Heating by electric, magnetic or electromagnetic fields
    • H05B6/02Induction heating
    • H05B6/10Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12Cooking devices
    • H05B6/1209Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1245Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements
    • H05B6/1263Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements using coil cooling arrangements

Abstract

Formas cristalinas polimórficas del antibiótico rifaximina (INN) denominadas rifaximina a y rifaximina b y una forma pobremente cristalina denominada rifaximina g. Estas formas son de utilidad en la producción de preparaciones medicinales para uso por vía oral y tópica y se pueden obtener por medio de un proceso de cristalización llevado a cabo por disolución en caliente de la rifaximina cruda en alcohol etílico y por cristalización del producto mediante la adición de agua a una temperatura determinada y por un período de tiempo determinado. La cristalización es seguida de un secado llevado a cabo bajo condiciones controladas hasta alcanzar un contenido de agua específico en el producto final. Reivindicación 1: Una rifaximina alfa purificada, un polimorfo del antibiótico rifaximina, caracterizada porque dicha rifaximina alfa presenta un contenido de agua menor que un 4,5% y produce un difractograma de polvo por rayos X que presenta picos en valores de ángulos de difracción 2theta de 6,6s, 7,4s; 7,9s; 8,8s; 10,5s; 11,1s; 11,8s; 12,9s; 17,6s; 18,5s; 19,7s; 21,0s; 21,4s; 22,1s. Reivindicación 6: Un proceso para la producción de las rifaximinas alfa, beta y gamma, caracterizado porque comprende: hacer reaccionar un equivalente molar de rifaximina O con un exceso de 2-amino-4-metilpiridina en una mezcla de solventes compuesta de agua y alcohol etílico en una relación volumétrica que comprende entre 1:1 y 2:1, por un período de tiempo entre 2 y 8 horas, a una temperatura entre 40sC y 60sC, tratar la masa de reacción a temperatura ambiente con una solución de ácido ascórbico en una mezcla de agua, alcohol etílico y ácido clorhídrico acuoso concentrado, ajustar el pH de la masa de reacción en pH 2,0 con una solución acuosa concentrada de ácido clorhídrico, filtrar la suspensión, lavar todo sólido resultante con la mezcla de solventes de agua/alcohol etílico para obtener una rifaximina cruda, purificar la rifaximina cruda por disolución de la misma en alcohol etílico a una temperatura que comprende entre 45sC y 65sC, hacer precipitar la rifaximina cruda por adición de agua y por disminución de la temperatura de la suspensión a un valor entre 0sC y 50sC bajo agitación por un período de tiempo entre 4 y 36 horas, filtrar la suspensión, lavar el sólido resultante con agua, y secarlo bajo vacío o bajo condiciones de presión normal, con o sin un agente de secado, a una temperatura entre temperatura ambiente y 105sC, por un período de tiempo entre 2 y 72 horas.
ARP040100781A 2003-11-07 2004-03-11 Formas polimorficas de rifaximina, procesos para su produccion y uso de las mismas en preparaciones medicinales AR043547A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT002144A ITMI20032144A1 (it) 2003-11-07 2003-11-07 Forme polimorfe di rifaximina, processi per ottenerle e

Publications (1)

Publication Number Publication Date
AR043547A1 true AR043547A1 (es) 2005-08-03

Family

ID=33187382

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP040100781A AR043547A1 (es) 2003-11-07 2004-03-11 Formas polimorficas de rifaximina, procesos para su produccion y uso de las mismas en preparaciones medicinales
ARP110102194A AR081992A2 (es) 2003-11-07 2011-06-23 FORMA POLIMORFICA g DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS
ARP110102193A AR081991A2 (es) 2003-11-07 2011-06-23 FORMA POLIMORFICA b DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP110102194A AR081992A2 (es) 2003-11-07 2011-06-23 FORMA POLIMORFICA g DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS
ARP110102193A AR081991A2 (es) 2003-11-07 2011-06-23 FORMA POLIMORFICA b DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS

Country Status (38)

Country Link
US (5) US7045620B2 (es)
EP (6) EP1676848B1 (es)
JP (5) JP2005139161A (es)
KR (4) KR20050043589A (es)
CN (4) CN1613858A (es)
AR (3) AR043547A1 (es)
AT (3) ATE421966T1 (es)
AU (2) AU2004200964A1 (es)
BR (2) BRPI0402382A (es)
CA (2) CA2460384A1 (es)
CL (1) CL2004000498A1 (es)
CO (1) CO5560083A1 (es)
CY (3) CY1108017T1 (es)
DE (4) DE602004019298D1 (es)
DK (3) DK1676848T3 (es)
ES (3) ES2320161T3 (es)
HK (3) HK1092150A1 (es)
HR (2) HRP20040265A2 (es)
IL (2) IL160798A0 (es)
IT (1) ITMI20032144A1 (es)
JO (1) JO2470B1 (es)
MA (1) MA27069A1 (es)
MD (1) MD3653G8 (es)
ME (1) ME00424B (es)
MX (2) MXPA04002353A (es)
NO (1) NO334950B1 (es)
NZ (1) NZ531622A (es)
PL (3) PL1557421T3 (es)
PT (3) PT1676847E (es)
RS (4) RS54569B1 (es)
RU (1) RU2270200C2 (es)
SI (3) SI1676847T1 (es)
TN (2) TNSN04044A1 (es)
TW (1) TWI285107B (es)
UA (1) UA86384C2 (es)
WO (1) WO2005044823A2 (es)
YU (1) YU24804A (es)
ZA (1) ZA200401948B (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
EP1698630B1 (en) * 2005-03-03 2014-09-03 ALFA WASSERMANN S.p.A. New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
JP5844961B2 (ja) 2006-08-02 2016-01-20 サリックス ファーマシューティカルズ, インコーポレイテッド 放射線直腸s状結腸炎を処置するための組成物および方法
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
KR101667534B1 (ko) * 2006-09-22 2016-10-19 씨아이피엘에이 엘티디. 리팍시민
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
WO2009008005A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
ES2798253T3 (es) * 2007-07-06 2020-12-10 Lupin Ltd Composiciones farmacéuticas de rifaximina
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
SG188931A1 (en) 2008-02-25 2013-04-30 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
KR20100122937A (ko) 2008-02-26 2010-11-23 샐릭스 파마슈티컬스 리미티드 장 질환의 치료 방법
AU2009244190B2 (en) 2008-05-07 2016-02-25 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
CN102164599B (zh) 2008-09-26 2014-07-23 Aska制药株式会社 预防和/或治疗功能性胃肠障碍的药剂
US7928115B2 (en) * 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US20100317681A1 (en) * 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
DK2350096T3 (da) * 2008-10-02 2020-03-02 Salix Pharmaceuticals Ltd Fremgangsmåder til behandling af hepatisk encephalopati
KR20110107806A (ko) 2008-12-10 2011-10-04 시플라 리미티드 리팍시민 복합체
IT1397617B1 (it) * 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
KR20120025578A (ko) * 2009-06-02 2012-03-15 샐릭스 파마슈티컬스 리미티드 간성 뇌병증의 치료방법
EP2475392A4 (en) * 2009-09-13 2013-01-09 Salix Pharmaceuticals Ltd METHOD FOR TREATING IRRITATION SYNDROME
KR20140015140A (ko) * 2009-10-27 2014-02-06 루핀 리미티드 리팍시민의 고형 분산물
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
WO2011061519A2 (en) 2009-11-23 2011-05-26 Cipla Limited Topical foam composition
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
AU2011218129A1 (en) 2010-02-18 2012-08-23 Board Of Regents Of The University Of Texas System Methods for treating infection
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
JP2013527246A (ja) * 2010-06-03 2013-06-27 サリックス ファーマシューティカルズ リミテッド リファキシミンの型およびその使用
WO2011156897A2 (en) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
MY165086A (en) 2010-07-12 2018-02-28 Salix Pharmaceuticals Ltd Formulations of rifaximin and uses thereof
US8759513B2 (en) 2010-09-13 2014-06-24 Sequent Scientific Limited Polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) * 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (es) * 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Proceso para la preparación de rifaximina amorfa
WO2012076832A1 (en) * 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
JP6076267B2 (ja) 2011-02-11 2017-02-08 サリックス ファーマスーティカルズ,リミテッド リファキシミンの形態およびその使用
CA2834829A1 (en) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
EP2773205A4 (en) * 2011-11-02 2015-03-25 Salix Pharmaceuticals Ltd METHOD FOR TREATING IRRITATION SYNDROME AND INFECTIONS
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
US9359374B2 (en) 2012-06-13 2016-06-07 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014091432A1 (en) 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
EP2971062A2 (en) 2013-03-15 2016-01-20 ALFA WASSERMANN S.p.A. Method for diagnosing vaginal infections
MX2015011802A (es) 2013-03-15 2016-01-08 Alfa Wassermann Spa Rifaximina para usarse en el tratamiento de infecciones vaginales.
US20140308350A1 (en) 2013-04-12 2014-10-16 Alfa Wassermann S.P.A. Nsaid administration and related compositions, methods and systems
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
US9765088B2 (en) 2014-04-19 2017-09-19 Granules India Limited Process for the preparation of rifamycin derivatives
WO2015171493A1 (en) 2014-05-04 2015-11-12 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
PL3546464T3 (pl) 2014-05-12 2020-11-02 Alfasigma S.P.A. Sposób wytwarzania i zastosowanie postaci krystalicznej Tau rifaksyminy solwatowanej z DEGME
MX2016016458A (es) * 2014-06-30 2017-07-13 Salix Pharmaceuticals Inc Métodos para repetir tratamiento de síndrome del intestino irritable (ibs).
CN104083324B (zh) * 2014-07-10 2017-05-10 青岛动保国家工程技术研究中心有限公司 一种利福昔明的兽用悬乳剂及其制备方法和应用
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
CN104274391B (zh) * 2014-10-08 2017-02-01 哈尔滨坤盟医药科技有限公司 一种含利福昔明的药物制剂
WO2017021975A1 (en) * 2015-08-06 2017-02-09 Msn Laboratories Private Limited Process for the preparation of crystalline forms of rifaximin
EP3536311B1 (en) 2016-03-24 2021-12-22 Sandoz AG Storage stable composition comprising rifaximin alpha
HUE056045T2 (hu) 2016-03-24 2022-01-28 Sandoz Ag Rifaximin alfa és delta tartalmú gyógyászati készítmény
US9988398B2 (en) * 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
ES2929768T3 (es) 2016-09-30 2022-12-01 Salix Pharmaceuticals Inc Formas sólidas de dispersión de rifaximina
CN106632396B (zh) * 2017-01-06 2019-01-11 成都樵枫科技发展有限公司 γ晶型利福昔明的制备方法和用途
US11052071B2 (en) * 2017-04-26 2021-07-06 Sandoz Ag Oral dosage form comprising rifaximin in form beta
RU2020102511A (ru) 2017-06-26 2021-07-27 Биофер С.П.А. Соединения пиридо-имидазо рифамицина в качестве антибактериального средства
CA3142214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
JP2022548788A (ja) 2019-09-24 2022-11-21 バウシュ ヘルス アイルランド リミテッド リファキシミン液体製剤
WO2021191312A1 (en) 2020-03-24 2021-09-30 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
WO2021229480A1 (en) * 2020-05-15 2021-11-18 Atra Pharmaceuticals Limited Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin
US20230277447A1 (en) 2020-06-26 2023-09-07 Bausch Health Ireland Limited Targeted release rifaximin compositions
US20230398102A1 (en) 2020-10-29 2023-12-14 Bausch Health Ireland Limited Rifaximin liquid formulations for use inthe treatment of sickle cell disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241785A (en) * 1978-07-24 1980-12-30 Peerless Of America, Inc. Heat exchangers and method of making same
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
EP0536197B1 (en) * 1990-06-29 1995-07-26 GRUPPO LEPETIT S.p.A. Pure crystalline form of rifapentine
WO2001051919A2 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
WO2002036542A1 (en) * 2000-10-31 2002-05-10 Ciba Specialty Chemicals Holding Inc. Crystalline forms of venlafaxine hydrochloride
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20050262269A1 (en) 2004-05-20 2005-11-24 Pike Jimmy D System and method for information handling system PCI express advanced switching
EP1698630B1 (en) 2005-03-03 2014-09-03 ALFA WASSERMANN S.p.A. New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
KR101667534B1 (ko) * 2006-09-22 2016-10-19 씨아이피엘에이 엘티디. 리팍시민
WO2008115572A1 (en) 2007-03-21 2008-09-25 Theraquest Biosciences, Inc. Methods and compositions of nsaids
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
ES2798253T3 (es) 2007-07-06 2020-12-10 Lupin Ltd Composiciones farmacéuticas de rifaximina
WO2009008005A1 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
JP2011500552A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
SG188931A1 (en) 2008-02-25 2013-04-30 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof

Also Published As

Publication number Publication date
KR100855084B1 (ko) 2008-08-29
AU2004287601A1 (en) 2005-05-19
ATE361927T1 (de) 2007-06-15
CA2538546C (en) 2011-04-19
CY1108017T1 (el) 2013-09-04
US20050101598A1 (en) 2005-05-12
US20110160449A1 (en) 2011-06-30
KR100867751B1 (ko) 2008-11-10
DE04005541T1 (de) 2005-12-29
CY1108909T1 (el) 2014-07-02
DE602004006367C5 (de) 2019-04-04
MD20060080A (en) 2006-11-30
CO5560083A1 (es) 2005-09-30
ES2320160T4 (es) 2011-03-09
IL174271A0 (en) 2006-08-01
EP2208730A1 (en) 2010-07-21
ES2320160T3 (es) 2009-05-19
HRP20040265A2 (en) 2004-12-31
PL1557421T3 (pl) 2007-08-31
RS20150291A1 (en) 2015-10-30
CN1886408A (zh) 2006-12-27
DE602004019296D1 (de) 2009-03-19
DE602004006367D1 (de) 2007-06-21
ZA200401948B (en) 2004-04-29
AR081992A2 (es) 2012-10-31
MA27069A1 (fr) 2004-12-20
PL1676848T3 (pl) 2009-07-31
WO2005044823A3 (en) 2005-10-27
US7915275B2 (en) 2011-03-29
EP1557421A1 (en) 2005-07-27
RS20060168A (en) 2008-09-29
KR20070113326A (ko) 2007-11-28
US20120059023A1 (en) 2012-03-08
JP2014177500A (ja) 2014-09-25
JP2005139161A (ja) 2005-06-02
DK1676847T3 (da) 2009-05-11
ATE421965T1 (de) 2009-02-15
CN1886408B (zh) 2010-06-09
DE602004019298D1 (de) 2009-03-19
PL1676847T3 (pl) 2009-07-31
ES2244364T1 (es) 2005-12-16
DK1557421T3 (da) 2007-09-17
MXPA06002644A (es) 2006-06-06
DK1676848T3 (da) 2009-05-11
SI1557421T1 (sl) 2007-08-31
CA2538546A1 (en) 2005-05-19
PT1676848E (pt) 2009-04-09
RU2270200C2 (ru) 2006-02-20
US8173801B2 (en) 2012-05-08
RS54568B1 (en) 2016-06-30
BRPI0402382A (pt) 2005-06-28
PT1676847E (pt) 2009-04-09
CN101260114B (zh) 2012-11-28
ES2244364T3 (es) 2007-12-01
IL160798A0 (en) 2004-08-31
JO2470B1 (en) 2009-01-20
CA2460384A1 (en) 2005-05-07
ATE421966T1 (de) 2009-02-15
CY1108964T1 (el) 2014-07-02
EP1676847B1 (en) 2009-01-28
EP1676847A1 (en) 2006-07-05
JP5635376B2 (ja) 2014-12-03
CL2004000498A1 (es) 2005-03-11
HRP20060093B1 (hr) 2015-12-18
RU2004108953A (ru) 2005-10-27
UA86384C2 (uk) 2009-04-27
ITMI20032144A1 (it) 2005-05-08
ME00424B (me) 2011-10-10
NZ531622A (en) 2004-10-29
EP1676848B1 (en) 2009-01-28
AU2004200964A1 (en) 2005-05-26
AR081991A2 (es) 2012-10-31
EP2210893A1 (en) 2010-07-28
TWI285107B (en) 2007-08-11
BRPI0407149A (pt) 2006-02-07
YU24804A (sh) 2006-08-17
BRPI0407149A8 (pt) 2019-01-15
US8404704B2 (en) 2013-03-26
JP2011057698A (ja) 2011-03-24
HK1092150A1 (en) 2007-02-02
AU2004287601B2 (en) 2009-02-26
JP5199576B2 (ja) 2013-05-15
EP1682556A2 (en) 2006-07-26
NO334950B1 (no) 2014-08-04
SI1676847T1 (sl) 2009-06-30
KR20050043589A (ko) 2005-05-11
SI1676848T1 (sl) 2009-06-30
HK1092151A1 (en) 2007-02-02
EP1557421B1 (en) 2007-05-09
DE602004006367T2 (de) 2007-09-06
KR100883216B1 (ko) 2009-02-13
TW200515913A (en) 2005-05-16
TNSN04044A1 (en) 2006-06-01
RS20150292A1 (en) 2015-10-30
MD3653G8 (ro) 2016-08-31
RS54569B1 (en) 2016-06-30
MXPA04002353A (es) 2005-05-11
CN101260115A (zh) 2008-09-10
JP2011046738A (ja) 2011-03-10
KR20060110737A (ko) 2006-10-25
CN101260114A (zh) 2008-09-10
JP2007509904A (ja) 2007-04-19
HRP20060093A2 (en) 2006-05-31
IL174271A (en) 2010-12-30
MD3653F2 (en) 2008-07-31
ES2320161T3 (es) 2009-05-19
NO20061110L (no) 2006-04-19
TNSN06069A1 (en) 2007-10-03
KR20070113327A (ko) 2007-11-28
US20050272754A1 (en) 2005-12-08
WO2005044823A2 (en) 2005-05-19
US20080132530A1 (en) 2008-06-05
RS54571B1 (en) 2016-06-30
PT1557421E (pt) 2007-07-31
EP1676848A1 (en) 2006-07-05
CN101260115B (zh) 2011-11-23
CN1613858A (zh) 2005-05-11
US7045620B2 (en) 2006-05-16
AU2004287601B8 (en) 2009-03-05
HK1073657A1 (en) 2005-10-14

Similar Documents

Publication Publication Date Title
AR043547A1 (es) Formas polimorficas de rifaximina, procesos para su produccion y uso de las mismas en preparaciones medicinales
JP2022003052A (ja) リファキシミン
RU2007136430A (ru) Новые полиморфные формы рифаксимина, способы их получения и их применение в лекарственных препаратах
ES2621557T3 (es) Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
US2984686A (en) 6-deoxy-6-demethyl-6-methylene-5-oxytetracyclines
CN103145636B (zh) 一种1,4-二酰基-3,6-二苯基-1,4-二氢均四嗪类化合物及其制备方法和应用
CA1303028C (en) Metal complexes of n-methyl-11-aza-10-deoxo-10- dihydroerythromycina or 11-aza-10-deoxo-10- dihydroerythromycin a, method for the manufacture thereof and their use in the manufacture of pharmaceuticals
WO2006035291A1 (en) Crystalline forms of cefdinir potassium
WO2012060675A1 (es) Proceso para la preparación de rifaximina amorfa
CN103450310A (zh) 豆甾醇衍生物及其在制备抗癌药物中的应用
JP6883593B2 (ja) 9−アミノメチル基置換のテトラサイクリン系化合物の結晶型及びその製造方法
FI62311B (fi) Foerfarande foer framstaellning av kristallint natrium- och kaiumcefalexinmonohydrat
CN108610347B (zh) 一种多羰基取代六元半瓜环的化合物及其制备方法
CA2975022C (en) Polymorphic forms of minocycline base and processes for their preparation
CN106187799B (zh) 一种制备dl-赖氨酸盐酸盐的方法
CN106798739B (zh) 一种用于治疗肿瘤疾病的药物
CN105198834B (zh) 2,6‑二溴苯并噻唑的合成工艺
JPS606957B2 (ja) 抗生物質誘導体の製造方法
CN104262336B (zh) 一种黄藤素酰腙类衍生物及其制备方法和用途
CN106800538B (zh) 一种苯并咪唑衍生物及其合成方法
CN104628820B (zh) 普那霉素ia晶型及其制备方法
CN104130164B (zh) 外消旋体紫草素萘茜母核羟基甲基化磺酸钠衍生物
CN109575053A (zh) 一种锌配合物及其制备方法
CN112940017A (zh) 一种含有锌螯合物的水凝胶材料
JPH03170485A (ja) 新規なオキサゾピロロキノリン化合物

Legal Events

Date Code Title Description
FB Suspension of granting procedure
FC Refusal
FC Refusal
FC Refusal